A 16-year-old boy with a history of severe persistent asthma despite treatment with inhaled corticosteroids presents for evaluation. Treatment with omalizumab, a monoclonal anti-IgE antibody, is recommended. This agent has been found to reduce the frequency of exacerbations of asthma in clinical trials. It is not known how the efficacy of omalizumab compares with that of other available therapies. The drug is more expensive than other agents.
No takes yet. Share an insight, caveat, or question.
Strunk et al. (2006) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: